Kornimate/medical-research-clean huggingface dataset:
study of zanzalintinib (xl092) + ab521 and zanzalintinib + ab521 + nivolumab in participants with advanced clear cell renal cell carcinoma (ccrcc) or other advanced solid tumors (stellar-009)

Conditions: Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors

Summary: the goal of this clinical trial is to learn about the safety and preliminary antitumor activity of zanzalintinib in combination with ab521 (doublet) and in combination with ab521 plus nivolumab (triplet) in participants with advanced ccrcc or other advanced solid tumors. the main questions it aims to answer are: * the recommended doses (rds) * the safety and tolerability * the pk and the preliminary efficacy


Eligibility criteria:
key inclusion criteria: 1. participants with a).unresectable advanced or metastatic solid tumor; b). unresectable advanced or metastatic clear cell renal cell carcinoma and no prior anticancer therapy; or c). unresectable advanced or metastatic clear cell renal cell carcinoma and has received at least one prior anticancer therapy. 2. measurable disease according to response evaluation criteria in solid tumors version 1.1 (recist 1.1; eisenhauer et al, 2009) as determined by the investigator. 3. for all participants, archival tumor tissue material should be obtained; if archival tissue is not available or is older than 2 years, then a fresh biopsy should be obtained, if medically feasible. specific requirements for tumor tissue samples will be described in the laboratory manual. 4. recovery to baseline or ≤ grade 1 per common terminology criteria for adverse events (ctcae) v5 from ae(s) related to any prior treatments unless ae(s) are deemed clinically nonsignificant by the investigator and/or stable on supportive therapy. 5. karnofsky performance status (kps) ≥70%. 6. screening ambulatory oxygen saturation (spo2) ≥92%. 7. screening left ventricular ejection fraction (lvef) above the institutional lower limit of normal. key exclusion criteria: 1. participants who have been previously treated with a hif-2α targeted therapy and/or zanzalintinib. 2. radiation therapy for bone metastases within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. participants with clinically-relevant ongoing complications from prior radiation therapy are not eligible. 3. known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment. 4. concomitant anticoagulation with oral anticoagulants except for a). prophylactic use of low-dose aspirin for cardioprotection or low dose low molecular weight heparins (lmwh) or b). therapeutic doses of lmwh or specified direct factor xa inhibitors. 5. administration of a live, attenuated vaccine within 30 days prior to enrollment. note: other protocol defined inclusion/exclusion criteria may apply.
influence of vitamin d on inflammatory bowel disease remission

Conditions: Inflammatory Bowel Disease

Summary: vitamin d has been shown to influence a multitude of systems. we intend to see whether different types of vitamin d supplements have an effect on inflammatory bowel disease.


Eligibility criteria:
inclusion criteria: * mild to moderate inflammatory bowel disease exclusion criteria: * hypersensitivity to milk products
exemestane + celecoxib vs exemestane + placebo in metastatic breast cancer

Conditions: Metastatic Breast Cancer

Summary: to discover if the adding of a coxib increases the efficacy of the aromasine.


Eligibility criteria:
inclusion criteria: * femal patient aged \> 18 years * histologically proven breast cancer * menopausal patient according to the following definition: * amenorrhoea \> 1 year or menopause affirmed by a rate of oestradiol or hypophyseal gonadotrophin * surgical ovariectomy * treatment by lhrh analog * ovarian suppression by radiotherapy * amenorrhoea induced by chemotherapy \> 1 year * oestradiol and/or progesterone positive receptors * presence of one or several metastatic lesion: * mesurable lesion * bone metastase were detected by bone scintigraphy * patient who can have received: * adjuvant chemotherapy and/or hormonotherapy (tamoxifen) * metastatic treatment by chemotherapy * ps \< 2 * adequate biological values * patient who has clearly given her consent by signing on informed consent form prior to participation exclusion criteria: * patient previously treated with hormonotherapy in metastatic phase * antecedent of treatment with aromatase inhibitors * local relapse (with the exception of cutaneous thoracic nodes) * patient with only one metastatic lesion like: pleurisy , ascites, lung lymphangitis carcinomatosa
comparing intermediate-dose ctx+ g-csf plus or not rhtpo for pb cd34+ cells mobilization in mm patients

Conditions: Multiple Myeloma

Summary: comparing intermediate-dose ctx (id-ctx)and g-csf with rhtpo or without for peripheral blood stem cell mobilization in patients with multiple myeloma, try to find out whether rhtpo combined to id-ctx + g-csf could improve the results of peripheral blood stem cell mobilization.

the purpose of this study is to try to find out whether rhtpo combined to id-ctx + g-csf could improve the results of peripheral blood stem cell mobilization. comparing id-ctx and g-csf plus rhtpo or not for peripheral blood stem cell mobilization in patients with multiple myeloma. rhtpo15000u/d were given from day 5\~7 after chemotherapy until the stem cell collection .

Eligibility criteria:
inclusion criteria: * diagnosed mm fulfill the international myeloma working group (imwg) criteria for mm diagnosis * eastern cooperative oncology group (ecog) performance status smaller than 2 and a life expectancy of more than 6 months * age at least 18 ys , no more than 70 ys old * no active infectious disease; no severe organ failure (except renal failure secondary to mm) * all screening procedures and evaluations should be completed * all patients should provide written informed consent. exclusion criteria: 1. severe impaired liver function; hiv positive or had active hepatitis a, b or c infection; hepatitis b virus-dna more than 10\^4/l;aspartate aminotransferase ( ast) and alanine aminotransferase (alt) more than 2.5 upper limit of normal (uln) 2. any disease that could put patients at high risk, including but not limited to unstable cardiac disease, defined as myocardial infarction in the previous 6 months, new york heart association (nyha) class iii-iv heart failure, uncontrolled atrial fibrillation or hypertension 3. severe prior thrombosis-event 4. history of other malignancy, unless cured for more than 3 years 5. pregnancy, lactation or disagreement to take contraceptive measures 6. severe infectious disease (uncured tuberculosis, pulmonary aspergillosis) 7. epilepsia, dementia or any mental disease requiring treatment.

Keywords: hematopoietic stem cell mobilization thrombopoietin
art compared to the hall technique for management hspm

Conditions: Hypomineralization, Tooth

Summary: aims: evaluation of treatment success on hspm-affected molars after art and hall technique. comparison of pain during treatment with art and hall technique in hspm. comparison of child and parent satisfaction with restorations used by art and hall technique. design: a randomized, controlled, crossover clinical study including thirty children.

background and aims: despite the widespread prevalence of hspm: there are no comparative studies yet between art and hall technique in the restoration of hspm. there are no studies yet on the success of art in the treatment of hspm. design: a randomized, controlled, crossover clinical study including thirty children each child will apply both of art and hall technique to him.

Eligibility criteria:
inclusion criteria: * absolute positive, positive or negative behavior according to the frankel scale. * healthy, both physically and mentally. * do not take medications that interfere with the assessment of pain within 24 hours prior to treatment. * a child with hspm-affected primary second molars on the right and left side in one jaw. * the hspm affected teeth from 2-6 degree in ghanim scale. * teeth with atypical carious lesions. * teeth with post-eruption destroyed * the presence of a clear, intact dentinal bridge between the caries and pulp radially. exclusion criteria: * allergy to the substances used in restoration. * presence of general or developmental medical conditions. * teeth with pulpitis inflammation or apical lesion or non-restorable. * teeth closed to being replaced.

Keywords: art hall technique hspm children restoration
effects of home-based physical activity in saudi arabian type-2 diabetes mellitus patients.

Conditions: Diabetes Mellitus, Type 2

Summary: the world health organization ranks saudi arabia as having the 7th highest rate of type-2 diabetes in the world. this therefore makes diabetes the most challenging health problem facing saudi arabia. importantly, physical activity has been shown to improve disease symptoms and overall health in patients with type-2 diabetes. however, findings relating to the prevalence of physical inactivity in the saudi population confirm that a sedentary lifestyle is on the rise, within physical inactivity levels in adults being 80.5%. therefore, interventions aimed at reducing physical inactivity using bespoke modalities pertinent to saudi arabia are clearly warranted. the purpose of this research project is to undertake a feasibility randomised control trial, examining the effects of a 12-week home-based physical activity programme on hba1c, blood lipids, fasting glucose and other indices of health-related quality of life in saudi arabian adults with type-2 diabetes.


Eligibility criteria:
inclusion criteria: * clinically established diagnosis of type-2 diabetes for at least 12 months * previously sedentary * knowledgeable about hypoglycemia * aged over 18 years * capacity to give informed consent. exclusion criteria: * cognitive impairment precluding consent or participation * pregnancy * additional medical conditions that prevent safe physical activity (e.g. severe arthritis or advanced heart failure) * enrolment in any other clinical trial designed to influence type-2 diabetes symptoms.
young people aged 18-25 with depression or anxiety mood participate in an llm-based digital dialogue intervention study

Conditions: LLM-based AI Dialogue Bot; Depression; Anxiety

Summary: this study is a 28-day randomized controlled trial (rct). residents were randomly assigned to an intervention group or a waiting group according to the order in which they were successfully contacted by the staff, and each user was asked to engage in a total of 28 days of dialog intervention with the douyin companion bot and complete three psychological questionnaires (on days 1, 14, and 28); however, the intervention group began to receive the dialog intervention after completing the first questionnaire, and the waiting group began to receive the dialog intervention after completing the third questionnaire. during the first four weeks, the waiting group was treated as a blank control. the two groups of subjects completed the three questionnaires at exactly the same point in time. each user's depression, anxiety, and positive and negative emotions were measured using the patient health questionnaire (phq-9), the generalized anxiety disorder scale (gad-7) and the positive and negative affect schedule (panas), respectively.


Eligibility criteria:
inclusion criteria: * 18-25 years old * proficient in chinese * not dyslexic * scoring at least 5 on the phq-9 or gad-7 * not having a serious physical or diagnosed mental illness exclusion criteria: * unwilling to continue to participate in the study * insufficient clocking in
natural killer (nk) cell transplantation for aml

Conditions: Acute Myeloid Leukemia

Summary: the purpose of this study is to assess the safety and efficacy of infusing natural killer cells from a donor as treatment for patients with acute myeloid leukemia in remission or who have experienced relapse.

natural killer (nk) cells extracted from a \[parental\] donor are infused intravenously. most patients are given a multi-agent chemotherapeutic conditioning regimen prior to the infusion. the conditioning regimen may be omitted for patients who have previously received traditional stem cell transplant. details of treatment plan: stratum 1 (aml in complete remission) cyclophosphamide 60 mg/kg iv day -7 fludarabine 25 mg/m2/day iv days -6 through -2 donor pheresis day -1 start il-2 on day -1, then 3 times per week x 2 weeks nk cell purification and infusion on day 0 stratum 2 (aml that is refractory or relapsed or aml with increasing minimal residual disease) clofarabine 40 mg/m2 iv, days -6 through -2 etoposide 100 mg/m2 iv, days -6 through -2 cyclophosphamide 400 mg/m2 iv, days -6 through 02 donor pheresis day -1 start il-2 day -1, and then 3 times per week x 2 weeks nk cell purification and infusion on day 0. for patients who have received prior sct, the conditioning regimen may be omitted if the nk cells are obtained from the original sct donor. cytokine regimen (stratum 1 and 2): 1 million units/m2 of il-2 given subcutaneously three times per week for two weeks (6 doses) starting on the evening of day -1. nk cell transplantation (stratum 1 and 2): nk cells from haplo-identical family donor will be infused on day 0.

Eligibility criteria:
inclusion criteria: * participants with aml that is in complete remission, is relapsed or refractory, or with increasing minimal residual disease. * participants in complete remission must have recovered from toxicity of previous therapy and have evidence of bone marrow recovery * participants who had prior stem cell transplant (sct) must have no evidence of gvhd and 60 or more days have elapsed since the sct. exclusion criteria: * participants who are pregnant * participants with inadequate renal, liver, or pulmonary functions

Keywords: leukemia myeloid acute
telecounselling for asthma counseling

Conditions: Asthma

Summary: in the coronavirus 2019 pandemic, on-the-job training for asthma counseling becomes more difficult. telecounseling as a training platform becomes a mainstream of training during the pandemic. this study is designed to fill the knowledge gap for telecounseling as a training platform for asthma counseling among nurses.

asthma education is essential in improving outcomes in asthma management. patients with asthma exacerbation frequently present to the urgent care centre or emergency department for emergency treatment. nurse-led asthma education was considered as beneficial to asthma management. however, not all nursing staff in the urgent care centre and emergency department are equipped with skills to counsel patients regarding their asthma control and inhaler use. it is important to empower the nursing staff with these skills such that the care of patients with asthma is not compromised. in the coronavirus 2019 pandemic, on-the-job training for asthma counseling becomes more difficult. asthma counseling trainers were usually in the clean zones but recipients of asthma counseling training were usually in the dirty zones. telecounseling as a training platform becomes a mainstream of training during the pandemic. telehealthcare interventions on patients with asthma was proven to reduce hospitalization over a 12-month period in a previous meta-analysis. however, there was no study investigating the efficacy of telecounseling to replace on-the-job training for asthma counseling. this study is designed to fill the knowledge gap for telecounseling as a training platform for asthma counseling among nurses.

Eligibility criteria:
including criteria: * registered nurses * nurses undergoing a training for asthma telecounseling * age 21 or more. excluding criteria: * nurses with previous training for asthma counseling * nurses who do not take care of patients with asthma * pregnant women
a phase ii trial of ridaforolimus and exemestane, compared to ridaforolimus, dalotuzumab and exemestane in participants with breast cancer (mk-8669-064)

Conditions: Breast Neoplasms

Summary: the purpose of the study is to evaluate the efficacy of the triplet of ridaforolimus, dalotuzumab and exemestane compared to the combination of ridaforolimus and exemestane in post-menopausal participants with breast cancer. the primary hypothesis of the study is that the triplet of ridaforolimus, dalotuzumab and exemestane will improve progression free survival (pfs) compared to ridaforolimus and exemestane.


Eligibility criteria:
inclusion criteria: * females with a histologically confirmed diagnosis of breast cancer that is metastatic or locally advanced (locally advanced tumors must not be amenable to surgery or radiation therapy with curative intent) with the following pathological characteristics determined locally: estrogen receptor positive and human epidermal growth factor receptor 2 (her-2) negative, and ki67 (a tumor marker) ≥ 15% determined by the central study laboratory * post-menopausal * with advanced breast cancer whose disease was refractory to previous letrozole or anastrozole * has at least one confirmed measurable metastatic lesion * has a performance status ≤ 1 on the eastern cooperative oncology group (ecog) performance scale * has a life expectancy of at least 3 months * adequate organ function exclusion criteria: * is receiving any other concurrent systemic tumor therapy, including hormonal agents and her-2 inhibitors * previously received rapamycin or rapamycin analogs, including ridaforolimus, temsirolimus, or everolimus * received prior treatment with insulin-like growth factor 1 receptor (igf-1r) inhibitors, phosphatidylinositol 3-kinase (pi3k) inhibitors, or other experimental agents that target pi3k, protein kinase b (akt), or mammalian target of rapamycin (mtor) pathway * is receiving chronic corticosteroids administered at doses greater than those used for normal replacement therapy * has active brain metastasis or leptomeningeal carcinomatosis; patients with adequately treated brain metastases are eligible if they meet certain criteria * known allergy to macrolide antibiotics * has an active infection requiring antibiotics * significant or uncontrolled cardiovascular disease * poorly controlled type 1 or 2 diabetes * is known to be human immunodeficiency virus (hiv) positive * has a known history of active hepatitis b or c. healthy carriers of hepatitis b are not allowed on this study
community-based e-health program for older adults living with chronic diseases

Conditions: Diabetes Mellitus; Hypertension; Hyperlipidemias

Summary: with increased aging population, there is a higher rate of having chronic diseases and cognitive impairment. in order to achieve successful aging, it is important for community-dwelling older adults to perform better self-management with improved health literacy and various kinds of support. the study aims to develop a community-based e-health program (cehp) for older adults living with chronic diseases , evaluate the effectiveness of cehp, and refine the program based on the outcome measurement. a cluster controlled trial will be adopted. a follow-up process evaluation will be conducted to assess the acceptability, strengths and limitations of cehp based on the participants' perspectives. the research contributes to engage and empower older adults living in the community to manage their chronic condition, and foster collaboration with the goal of translating evidence into action.

background: with increased aging population, there is a higher rate of having chronic diseases and cognitive impairment. in order to achieve successful aging, it is important for community-dwelling older adults to perform better self-management with improved health literacy and various kinds of support. objectives: the study aims to develop a community-based e-health program (cehp), evaluate the effectiveness of cehp, and refine the program based on the outcome measurement. method: the research team will develop the community-based e-health program, and assess the effects of the program. a needs assessment will be carried out using focus group discussion with the older adults. a cluster controlled trial will be adopted. a follow-up process evaluation will be conducted to assess the acceptability, strengths and limitations of community-based e-health program based on the participants' perspectives discussion and conclusion: the proposed research contributes to engage and empower older adults living in the community to manage their chronic condition, and foster collaboration with the goal of translating evidence into action. this research will offer important insights into the need for educating and engaging older adults in managing chronic conditions to promote health and well-being, and therefore contribute to health and well-being of the elderly population.

Eligibility criteria:
inclusion criteria: 1) aged 60 or above; 2) able to understand and communicate in either english or mandarin; 3) able to give consent to participate; 4) lives within the community setting; 5) diagnosed with chronic conditions (hypertension, hyperlipidemia, and diabetes mellites); 6) able to commit to the research program throughout the whole duration. exclusion criteria: 1. severe cognitive impairment; 2. severe psychiatric disorders; 3. severe vision impairment; 4. severe hearing impairment.

Keywords: community-dwelling older adults chronic diseases self-management e-health cognitive impairment
cohort study of clinical and neuroimaging characteristics for bppv patients in china

Conditions: BPPV; Vertigo; Vertigo, Peripheral

Summary: the main objective is to analyze the abnormality of physical condition, mental health and blood examination of the patients with benign paroxysmal positional vertigo (bppv). besides, the investigators aim to establish a database of bppv based on multimodal magnetic resonance imaging data in the brain to identify high-risk patients with residual dizziness (rd) and systematically establish the comprehensive assessment system for the precise diagnosis, treatment and recovery of rd, optimize the tactics of bppv management in china.

this is an observational, longitudinal, and single-center study. confirmed bppv cases will complete the following programs before and after 1 and 6 months of treatment for exploring biological mechanism and predictive biomarkers of bppv: 1) fill in the behavioral psychological scales, 2) submit blood samples at a local laboratory, 3) receive 3 times brain mri scan. the healthy controls will complete the same programs as bppv-group mentioned above only at the time of inclusion. the investigators will establish the brain mri database containing neuropsychological scales and blood parameters of bppv in china.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of bppv/healthy subjects who have not had bppv exclusion criteria: * history of organic diseases in central nervous system and mental disorder, such as tumors, infections, depressive disorder, schizophrenia, etc. claustrophobic

Keywords: bppv residual dizziness vertigo neuroimaging epidemic